breast cancer

August 9, 2017

Stress may switch on bone “mets”

New findings could explain the link between chronic stress and reduced survival in women diagnosed with breast cancer, and could lead to new strategies to improve treatment outcomes.

By Bill Snyder
red three darts arrows in the target center
August 3, 2017

Investigators match novel cancer mutations with potential therapies

Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.

By VUMC News and Communications
July 20, 2017

Drivers of breast cancer metastasis

Signaling through a complex of proteins called mTORC2 plays a role in breast cancer migration, invasion and metastasis, Vanderbilt researchers reported.

By Leigh MacMillan
July 13, 2017

Arteaga to direct UT Southwestern cancer center

Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center in Dallas.

By VUMC News and Communications
bees
June 19, 2017

STINGing combination for cancer

A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.

By VUMC News and Communications
May 26, 2017

VICC experts to discuss high risk breast cancer at free seminar June 6

Vanderbilt-Ingram Cancer Center (VICC), in collaboration with the Hereditary Cancer Program and the Vanderbilt Breast Center, is hosting a free seminar, “Are You at High Risk for Breast Cancer?”

By VUMC News and Communications
April 20, 2017

Study examines new breast cancer drug combination

A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.
By VUMC News and Communications
March 30, 2017

Horn to lead lung cancer combination therapy trial

Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer.
By VUMC News and Communications
March 30, 2017

Research support

DS Services of America Inc. recently presented a $100,000 gift to Vanderbilt-Ingram Cancer Center (VICC) to support breast cancer research.
By VUMC News and Communications
March 23, 2017

Breast cancer program lands new research grants

Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients.
By VUMC News and Communications
January 16, 2017

Softening tumor tissue could aid cancer treatments

Tumors cause the intracellular material surrounding them to stiffen. Softening this protective layer could make existing cancer treatments more effective, according to new research.
By VUMC News and Communications
November 18, 2016

Targeting the “un-targetable”

A novel drug that targets the protein RSK blocked aggressive breast cancers from metastasizing in an animal model.
By VUMC News and Communications
September 29, 2016

BMI genotype and breast cancer risk

For breast cancer prevention, a new study provides evidence for lifestyle modification to reduce weight gain in adults.
By Paul Govern
1 … 4 5 6 7 8 … 12